About CMS

Current Location:About CMS > Business Introduction

Pharmaceutical Business

Innovative Research

With more than two decades experience in introduction of and investment in global products, CMS has accumulated extensive overseas channel resources and market reputation, and established a unique product evaluation system. Through industrial equity investment in innovative R&D companies and strategic cooperation with leading pharmaceutical companies around the world, the Group has made equity investments in a number of overseas R&D companies from the U.K., France, Switzerland, the U.S., etc. and established strategic cooperation with several world’s leading pharmaceutical companies; meanwhile, through equity investment in and establishment of joint venture with domestic cutting-edge biotech companies, the Group has initiated a new model for industrial investment in the innovative drug, achieving combination of complementary advantages and strong alliance to accelerate the R&D and commercialization progress of innovative products. As at 30 April 2021, the Group has more than 20 innovative products with relatively high innovation level, good market potential and competitive differentiation advantages; among them, 9 innovative products are approved for marketing in the U.S. and/or Europe, and the registration trials of 3 products are completed or underway.

Capitalizing on its extensive expert network and experienced clinical development teams, the Group strictly controls the core clinical processes such as clinical design, patient enrollment, quality control, etc. while cooperating with CROs, so as to achieve efficient and quality progress of clinical projects of innovative drugs.


Professional Academic Promotion

The Group has proven experience in market access, academic promotion and government affairs of prescription drugs for more than two decades, and has established a professional, compliant and efficient academic promotion system, with which the Group has built professional brand images and achieved good sales records for a number of quality branded drugs in China. Since 1998, the Group has started the campus recruitment for fresh graduates with bachelor or master degree in Medicine and Pharmacy, and has developed a comprehensive internal training system to establish a professional and compliant promotion team with strong execution; some professionals from the Group’s management team have medical working experience, understand the medication patterns of Chinese patients, and are able to develop precise product promotion strategies and efficiently implement the strategies.

As at 31 December 2020, Group’s academic promotion network covered approximately 57,000 hospitals and medical institutions in China, and the promotion team had around 3,300 professional promotion staff.


Pharmaceutical Manufacturing

The Group’s imported products are produced by entrusted overseas pharmaceutical manufacturers, while some of the domestic products are produced by the Group’s manufacturing plants. The Group has more than two decades of experience in pharmaceutical manufacturing, and has GMP-compliant pharmaceutical manufacturing sites in Hunan, Hebei and Shenzhen, which occupy a total area of more than 110,000 square meters, and owns Pharmaceutical Production Licenses for various dosage forms and Production Permits for imported drugs sub-packaging. The Group’s rich production experiences as well as its mature quality control system have laid an important foundation for localized preparation manufacturing of some overseas innovative products in China.



Dermatology and Medical Aesthetic Business

CMS enriched the dermatology line and entered the medical aesthetic filed through acquisition of Luqa Ventures, a dermatology specialty company. The Group will continuously utilize its domestic and overseas channel resources to deploy professional dermatological products and cutting-edge medical aesthetic solutions globally to build a comprehensive skin health product matrix consisting of prescription medicines, medical devices, medical aesthetic solutions and dermatology-grade skin care products; in the meantime, the Group will leverage its extensive network resources in the dermatology, and integrate hospital, medical institution, retail and internet channels to build a leading skin management and high-end medical aesthetic brand in China, with first-rate competitiveness, and fulfill the increasingly diverse needs for skin management and beauty of Chinese consumers.



Healthcare Business

Capitalizing on its strengths such as overseas channel resources accumulated for more than two decades, good reputation, unique product evaluation system, responsive global supply chain system, and strong promotion network, CMS stringently selects functional quality healthcare products with unique ingredients globally according to medical concept and high standards, and supplies the products to Mainland China through cross-border e-commerce platforms, so as to provide consumers with healthy lives.

"CMS Health Overseas Flagship Stores" has been officially launched on Youzan, JD and Tmall platforms. The flagship stores offer a full range of products that meet the all-round health care needs of people at different ages.